RA Capital Management OMDA Position
Exited4-Fund ConvergenceRA Capital Management exited their position in Omada Health, Inc. (OMDA) in Q3 2025, after holding the stock for 2 quarters.
The position was first reported in Q2 2025 and has been tracked across 2 quarterly 13F filings.
OMDA is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Omada Health, Inc.
Omada Health is a U.S.-based virtual-care provider offering clinically validated programs for chronic conditions like cardiometabolic disease, musculoskeletal care, and behavioral health—delivered digitally between doctor visits.
Full company profile →Short Interest
5.3%
1.7 days to cover
RA Capital Management OMDA Position History
Frequently Asked Questions
Does RA Capital Management own OMDA?
No. RA Capital Management exited their position in Omada Health, Inc. (OMDA) in Q3 2025. They previously held the stock for 2 quarters.
How many hedge funds own OMDA?
4 specialist biotech hedge funds currently hold OMDA, including Perceptive Advisors, Rock Springs Capital, Deerfield Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy OMDA?
RA Capital Management's position in OMDA was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's OMDA position increasing or decreasing?
RA Capital Management completely exited their OMDA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OMDACompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →